2.The Bone Response to Hormone Replacement Therapy according to Basal Bone Mineral Density in Postmenopausal Women.
Jung Gu KIM ; Kwang Rai KIM ; Byung Chul GEE ; Seok Hyun KIM ; Young Min CHOI ; Shin Yong MOON ; Jin Yong LEE
Korean Journal of Obstetrics and Gynecology 2001;44(8):1450-1454
OBJECTIVE: To investigate the incidence of non-responder to hormone replacement therapy (HRT) and to evaluate the bone response to HRT according to basal bone mineral density(BMD) in postmenopausal women. METHODS: A total of 211 postmenopausal women received either continuous combined estrogen-progestogen replacement (n=112) or estrogen replacement (n=99) for 1 years. BMD at the lumbar spine and femoral neck was measured by dual energy X-ray absorptiometry (DEXA) before and 1 year after HRT. RESULTS: The incidence of non-responder (women with > 3% bone loss per year) to HRT was 9.2% in the lumbar spine, and 23.8% in femoral neck. Estrogen replacement group had a higher incidence of non-responder than combined replacement group. Non-responder group had a higher basal BMD at the lumbar spine than responder group, and showed bone loss rate of 7.6% per year. After 1 year of HRT, postmenopausal women with osteoporosis showed a higher rate of increase in BMD at the lumbar sine and femoral neck than women with normal BMD or osteopenia. CONCLUSION: The non-responders to HRT have a higher basal lumbar BMD, compared with responders. The higher basal BMD at the lumbar spine is, the less bone conservation effect of HRT is.
Absorptiometry, Photon
;
Bone Density*
;
Bone Diseases, Metabolic
;
Estrogen Replacement Therapy
;
Female
;
Femur Neck
;
Hormone Replacement Therapy*
;
Humans
;
Incidence
;
Osteoporosis
;
Spine
3.Intravenous pamidronate treatment in Filipino children with moderate to severe osteogenesis imperfecta
Alcausin Maria Melanie B. ; de Dios John Karl L. ; Chiong Mary Anne D. ; Cavan Barbra Charina V. ; David-Padilla Carmencita ; Cutiongco-de la Paz Eva Maria
Acta Medica Philippina 2011;45(4):35-39
Objective. To present preliminary data on the effects of intravenous pamidronate in children with moderate to severe Osteogenesis Imperfecta (OI).
Methods. This is a restrospective study wherein a review of medical records and available serial radiographs of children (N=14) with moderate to severe IO started on pamidronate from 2006 to 2010 was done.
Results. Two children have IO Type I, 8 have IO Type III and 4 have IO Type IV. At baseline, 2 had normal height, 8 had height less than minus 2SD and the rest with less than minus 1SD. Twelve out of 14 had vertebral compression fractures. Mean age at start of pamidronate was 5.4 years (range 0.5-11 years). First infusion fever in five patients and transient generalized macular rash in one child were noted. Serum calcium and phosphorus levels were normal at baseline and remained stable. Based on parental report, improvement of motor function was noted. In the 10 children who had at least a year of treatment, long bone fractures decreased from mean annualized fracture rate of 2.6 at baseline to 0.9. In patients with vertebral compression fractures, serial radiographs showed improvement of vertebral shape.
Conclusion. This preliminary study shows that treatment was generally well tolerated and led to decrease in long bone fractures, improved vertebral shape and improved function.
Human
;
Male
;
Female
;
Child
;
Child Preschool
;
PAMIDRONATE
;
OSTEOGENESIS IMPERFECTA
;
MUSCULOSKELETAL DISEASES
;
BONE DISEASES
;
BONE DISEASES, DEVELOPMENTAL
;
BONE DISEASES, METABOLIC
;
OSTEOCHONDRODYSPLASIAS
;
THERAPEUTICS
;
THERAPY
;
OSTEOPOROSIS
4.Expert consensus on clinical management of metabolic bone disease of prematurity (2021).
Chang YAN-MEI ; Lin XIN-ZHU ; Zhang RONG ; Liu XI-HONG ; Tong XIAO-MEI ; Chen PING-YANG ; Feng ZHI-CHUN
Chinese Journal of Contemporary Pediatrics 2021;23(8):761-772
Metabolic bone disease of prematurity (MBDP) is a systemic bone disease with a reduction in bone mineral content due to disorder of calcium and phosphorus metabolism. There is still a lack of in-depth research and systematic understanding of MBDP in China, and there are many irregularities in clinical management of this disease. Based on relevant studies in China and overseas, Grading of Recommendations Assessment, Development and Evaluation was used to develop the expert consensus on the clinical management of MBDP, which provides recommendations from the following five aspects: high-risk factors, screening/diagnosis, prevention, treatment, and post-discharge follow-up of MBDP, so as to provide relevant practitioners with recommendations on the clinical management of MBDP to reduce the incidence rate of MBDP and improve its short- and long-term prognosis.
Aftercare
;
Bone Diseases, Metabolic/therapy*
;
Consensus
;
Humans
;
Infant, Newborn
;
Infant, Premature
;
Patient Discharge
5.Treatment and management of patients with inherited metabolic diseases.
Korean Journal of Pediatrics 2006;49(11):1152-1157
Inherited metabolic disease is rare disorders that show symptoms mainly in pediatric age and early treatment is important for preventing complications of the disease. Recent development in molecular and biochemical techniques help clinicians with proper diagnosis of patients, however, many of the disease still remain lack of effective therapeutic strategies. Better understanding on biochemical and molecular basis of pathogenesis of the disease combined with advanced medical care would provide new sight on the disease that can also improve the quality of life and long-term prognosis of patients. Traditionally, there are several modalities in the treatment of metabolic diseases depend on the biochemical basis of the disease such as diet restriction, removing or blocking the production of toxic metabolites, and stimulating residual enzyme activity. The inherited metabolic disease is not familiar for many clinicians because the diagnosis is troublesome, treatment is complicated and prognosis may not as good as expected in other diseases. Recently, new therapeutic regimens have been introduced that can significantly improve the medical care of patients with metabolic disease. Enzyme replacement therapy has showed promising efficacy for lysosomal storage disease, bone marrow transplantation is effective in some disease and gene therapy has been trying for different diseases. The new trials for treatment of the disease will give us promising insight on the disease and most clinicians should have more interest in medical progress of the metabolic disease.
Bone Marrow Transplantation
;
Diagnosis
;
Diet
;
Enzyme Replacement Therapy
;
Genetic Therapy
;
Humans
;
Lysosomal Storage Diseases
;
Metabolic Diseases*
;
Metabolism
;
Prognosis
;
Quality of Life
6.Bone mineral density changes after 4 years of hormone replacement therapy.
Jung Ryul LEE ; Jin Young CHA ; Hun Young CHO ; Yoo Kyung LEE ; Min Soo PARK ; Yoo Seok LEE ; Young Jeong NA ; Soo Hyun CHO ; Sam Hyun CHO ; Sung Ro CHUNG ; Youn Yeung HWANG
Korean Journal of Obstetrics and Gynecology 2002;45(12):2189-2195
OBJECTIVE: To evaluate the various effects of hormone replacement therapy (HRT) on bone mineral density (BMD) for 4 years in postmenopausal women and to compare the characteristics of non-responders to HRT. METHODS: A total of 100 postmenopausal women have been treated with HRT or estrogen replacement therapy for 4 years. Spinal BMD was measured by dual energy X-ray absorptiometry. RESULTS: The mean age and menopausal age of the study subjects was 53.3+/-3.6 and 4.7+/-4.0 years. According to the baseline BMD, 32 and 9 women were osteopenic and osteoporotic. Compared with the baseline value, the lumbar BMD increased significantly after one and two years of HRT, but after three years the rate of increment has slowed. However, the change of BMD has significantly increased again after four years of HRT (3.98%, 5.36%, 5.41%, 6.16%, in each year, respectively). Women with baseline osteopenia and osteoporotis gained significantly more BMD after 1 year of HRT than women with baseline normal BMD (p=0.02). There were no significant differences of BMD changes among the 3 treatment regimens (continuous combined, cyclic combined, and estrogen only). After 1 year of HRT, 14 non-responders were indentified who had reduced BMD (-1.7+/-1.6%) compared with baseline BMD whereas 86 responders had increased BMD (4.9+/-4.1%). In the non-responder, BMD increased in two year of HRT but decreased in the three and four year of HRT while BMD increased in the two, three and four year of HRT in responders. After 4 years of HRT, 17 nonresponders (-3.0%+/-1.8%) and 83 responders (8.2+/-7.1%) were indentified. There was no significant difference in age, year since menopause, body mass index and baseline BMD between non-responders and responders. However, non-responders loose their BMD after 1 and 4 year of HRT. CONCLUSION: After HRT, the BMD increased not only first and second year but also fourth year of treatment. The BMD changes did not different according to the treatment regimens. The lower the women's baseline BMD, the greater the BMD increase after HRT. After four years of HRT, 17% of women lose their BMD compared to baseline BMD. The BMD changes in the first year of HRT may be an important predictive factor for the long-term BMD response to HRT in postmenopausal women.
Absorptiometry, Photon
;
Body Mass Index
;
Bone Density*
;
Bone Diseases, Metabolic
;
Estrogen Replacement Therapy
;
Estrogens
;
Female
;
Hormone Replacement Therapy*
;
Humans
;
Menopause
;
Osteoporosis
7.Diagnosis and Treatment of Osteoporosis.
Khunying Kobchitt LIMPAPHAYOM ; Heung Yeol KIM
Kosin Medical Journal 2011;26(2):121-126
Osteoporosis is common among older adults and results in costly osteoporotic fractures. With the aging of the population, low bone mass states will be an increasing clinical issue for both men and women. Screening for this metabolic bone disorder is warranted in most old adults and clinicians must be diligent in identifying persons at risk. The evaluation should include an assessment of risk factors for falls, a bone density test, and consideration of possible secondary causes of osteoporosis. Several medications are available to improve bone density and decrease fractures. There are a variety of pharmaceutical agents that have been recommended for the treatment of osteopenia and osteoporosis including hormone replacement therapy, selective estrogen receptor modulator therapy, anti-resorptive therapy. In addition patients with osteoporosis who have failed anti-resorptive therapy can have a significant improvement in their bone density with anabolic therapy.
Adult
;
Aging
;
Bone Density
;
Bone Diseases, Metabolic
;
Female
;
Hormone Replacement Therapy
;
Humans
;
Male
;
Mass Screening
;
Osteoporosis
;
Osteoporotic Fractures
;
Risk Factors
;
Selective Estrogen Receptor Modulators
8.Effect of Antiepileptic Drugs on Bone Mineral Density and Bone Metabolism in Epileptic Patients.
Sang Won PARK ; Yong Won CHO ; Jae Hun HER ; Yong Euk SHIN ; Hyun Ah YI ; Jun LEE ; Hyung LEE ; Jeong Geun LIM ; Sang Doe YI
Journal of the Korean Neurological Association 2004;22(4):310-314
BACKGROUND: Bone mineral density (BMD) is influenced by genetic, hormonal, and environmental factors. Long-term antiepileptic drug (AED) use also causes osteopenia or osteoporosis that have been most extensively described in institutionalized patients. But, the mechanism of these abnormalities is unclear. The objective of this study is to determine the effect of AED on bone density and to explain the pathophysiologic mechanisms by analyzing bone related factors. METHODS: We prospectively examined BMD by dual-energy X-ray absorptiometry in 45 patients with epilepsy. We measured the serum calcium, phosphorus, protein, alkaline phosphatase (ALP), bone specific ALP, vitamin D and osteocalcin to analyze the factors that influence bone metabolism. RESULTS: BMD was significantly lower in the patient group than in the control group (p<0.05). 13% of patients had osteopenia and 3% of patients had osteoporosis. The level of bone specific ALP was higher in the patient group, but the level of vitamin D was not different, implying that BMD is decreased by the direct effect of antiepileptic drugs. There was a weak negative correlation and marginal significance between BMD and the duration of therapy in the patient group (r=-0.407, p<0.05). CONCLUSIONS: Long-term antiepileptic drug therapy in patients who have seizures causes significant bone loss in the lumbar spine even in the absence of vitamin D deficiency. In addition, the degree of bone mineral density was weakly related with the therapeutic duration of antiepileptic drugs. The regular evaluation of BMD in patients with long-term antiepileptic drugs might be helpful to prevent decreases in BMD.
Absorptiometry, Photon
;
Alkaline Phosphatase
;
Anticonvulsants*
;
Bone Density*
;
Bone Diseases, Metabolic
;
Calcium
;
Drug Therapy
;
Epilepsy
;
Humans
;
Metabolism*
;
Osteocalcin
;
Osteoporosis
;
Phosphorus
;
Prospective Studies
;
Seizures
;
Spine
;
Vitamin D
;
Vitamin D Deficiency
9.Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism.
Li-Juan YANG ; Fei-Xia SHEN ; Jing-Chen ZHENG ; Hai-Ling ZHANG
China Journal of Orthopaedics and Traumatology 2012;25(2):133-137
OBJECTIVETo evaluate the efficacy and safety of alendronate for the treatment of osteoporosis/osteopenia secondary to hyperthyroidism.
METHODSFrom April 2008 to November 2009, 27 patients with hyperthyroidism with osteoporosis/ osteopenia measured by dual energy X-ray absorptiometry (DXA) were included in this study, and then they were randomly divided into two groups (group A and group B) by simple random sampling. Group A consisted of 14 patients treated with antithyroid drug and caltrate D, the antithyroid drug change with thyroid function, and caltrate D 600 mg per day. Group B consisted of 13 patients treated with antithyroid drug, caltrate D and alendronate, antithyroid drug and caltrate D the same as group A, and alendronate 70 mg weekly. Meanwhile, 21 healthy voluntary adults were chosen as control group. And compared with the control group which was treated with nothing. Followed-up for one year, the bone mineral density (including T-score, Z-score, BMD) in lumbar spine (LS), femoral neck (FN) and distal radius (DR) and general information, were compared before and after treatment.
RESULTSBMD at FN and DR were significantly higher at 12 months after treatment than at the baseline in group A (P = 0.000); T-score, Z-score, and BMD at the LS, FN and DR were all significantly higher at 12 months after treatment than at the baseline in group B (P < 0.05), but these data could not arrive to normal level. In group A, the percentage increased in BMD at the LS, FN, and DR were (4.34 +/- 10.5)%, (3.21 +/- 1.38)%, (1.95 +/- 0.44)%, respectively, at 12 months after treatment. In group B, the percentage increased in BMD at the LS, FN, and DR were (6.10 +/- 8.12)%, (4.10 +/- 5.64)%, (3.10 +/- 3.23)%, respectively, at 12 months after treatment. There was significant difference in the rate of increase between two groups (P < 0.05). AKP decreased, weight, BMI increased, and thyroid function decreased, after treatment than those before in both of the two groups. (P < 0.05).
CONCLUSIONAlendronate can significantly increase BMD in treating patients with hyperthyroidism and osteoporosis/osteopenia. Compared with anti-thyroid drugs alone, treatment with alendronate can obtain more clinical effect and also very safety.
Adult ; Alendronate ; therapeutic use ; Bone Density ; Bone Density Conservation Agents ; therapeutic use ; Bone Diseases, Metabolic ; drug therapy ; etiology ; Female ; Humans ; Hyperthyroidism ; complications ; drug therapy ; Male ; Middle Aged ; Osteoporosis ; drug therapy ; etiology
10.Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
Jun-Hong DENG ; Liu-Ping YANG ; Liang-Sheng WANG ; De-Fan ZHOU
Asian Journal of Andrology 2004;6(1):75-77
AIMTo evaluate the effect of androgen deprivation therapy (ADT) on bone mineral density (BMD) in prostate cancer patients.
METHODSForty-nine prostate cancer patients with their BMD determined were divided into two groups: the non-treated group included 21 patients before the commencement of ADT and the treated group, 28 patients, who had received ADT for more than 1 year. BMD was measured by dual energy X-ray absorptiometry (DEXA) in the lumbar spine (L2-4) and femoral neck.
RESULTSThirteen (62 %) non-treated and 23 (82 %) treated patients fulfilled the BMD criteria for osteopenia or osteoporosis. Z scores for age-matched control in lumbar spine and femoral neck were -0.9 +/- 0.7 and -0.6 +/- 0.5, respectively, in the treated group, and -1.8 +/- 1.1 and -1.6 +/- 1.0, respectively, in the non-treated group, the differences between the two groups were highly significant (P<0.01).
CONCLUSIONProstate cancer patients who received ADT for more than 1 year had a significantly lower BMD in the lumbar spine and femoral neck than those before the beginning of ADT.
Absorptiometry, Photon ; Aged ; Aged, 80 and over ; Androgens ; deficiency ; Bone Density ; Bone Diseases, Metabolic ; diagnosis ; etiology ; Gonadotropin-Releasing Hormone ; therapeutic use ; Humans ; Male ; Orchiectomy ; adverse effects ; Osteoporosis ; diagnosis ; etiology ; Prostatic Neoplasms ; therapy